» Articles » PMID: 18397235

Susceptibility to Gut Leakiness: a Possible Mechanism for Endotoxaemia in Non-alcoholic Steatohepatitis

Overview
Journal Liver Int
Specialty Gastroenterology
Date 2008 Apr 10
PMID 18397235
Citations 114
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: One of the proposed second hit mechanisms in the pathophysiology of non-alcoholic steatohepatitis (NASH) is hepatic oxidative stress triggered by elevated levels of endotoxin. We investigated one possible mechanism for the endotoxaemia--disruption of intestinal barrier integrity.

Methods: We enrolled 16 subjects with fatty liver (10 NASH; 6 steatosis) and 12 healthy subjects. Steatosis and NASH were diagnosed by liver biopsy using the Brunt criteria. Gastrointestinal permeability was measured using urinary excretion of 5-h lactulose/mannitol (L/M) ratio and 24-h sucralose. Permeability testing was repeated after aspirin challenge.

Results: Groups had similar baseline urinary 0-5 h L/M ratio (small bowel permeability) and 0-24 h sucralose (whole-gut permeability). Aspirin increased 0-5 h urinary L/M in most subjects. In contrast, aspirin significantly increased whole-gut permeability only in NASH subjects. In fact, the major increase in the urinary sucralose occurred in the 6-24 h samples, which points towards the colon as the major site responsible for aspirin-induced leakiness in NASH patients. Serum endotoxin levels were significantly higher in NASH subjects.

Discussion: Our findings suggest that aspirin acts on the colon to unmask a susceptibility to gut leakiness in patients with NASH. This effect may be the underlying mechanism for increased serum endotoxin, which is the second hit (after altered lipid metabolism) that is required to initiate a necroinflammatory cascade in hepatocytes which are already primed with obesity-induced abnormal lipid homoeostasis.

Citing Articles

The oral-gut microbiota axis: a link in cardiometabolic diseases.

Xu Q, Wang W, Li Y, Cui J, Zhu M, Liu Y NPJ Biofilms Microbiomes. 2025; 11(1):11.

PMID: 39794340 PMC: 11723975. DOI: 10.1038/s41522-025-00646-5.


Multifunctional role of oral bacteria in the progression of non-alcoholic fatty liver disease.

Mei E, Yao C, Chen Y, Nan S, Qi S World J Hepatol. 2024; 16(5):688-702.

PMID: 38818294 PMC: 11135273. DOI: 10.4254/wjh.v16.i5.688.


Nisin lantibiotic prevents NAFLD liver steatosis and mitochondrial oxidative stress following periodontal disease by abrogating oral, gut and liver dysbiosis.

Kuraji R, Ye C, Zhao C, Gao L, Martinez A, Miyashita Y NPJ Biofilms Microbiomes. 2024; 10(1):3.

PMID: 38233485 PMC: 10794237. DOI: 10.1038/s41522-024-00476-x.


Metabolic Syndrome: A Narrative Review from the Oxidative Stress to the Management of Related Diseases.

Martemucci G, Fracchiolla G, Muraglia M, Tardugno R, Dibenedetto R, DAlessandro A Antioxidants (Basel). 2023; 12(12).

PMID: 38136211 PMC: 10740837. DOI: 10.3390/antiox12122091.


Oral Pathogenic Bacteria and the Oral-Gut-Liver Axis: A New Understanding of Chronic Liver Diseases.

Lei Y, Li S, He M, Ao Z, Wang J, Wu Q Diagnostics (Basel). 2023; 13(21).

PMID: 37958220 PMC: 10648517. DOI: 10.3390/diagnostics13213324.


References
1.
Hollander D . Intestinal permeability, leaky gut, and intestinal disorders. Curr Gastroenterol Rep. 2000; 1(5):410-6. DOI: 10.1007/s11894-999-0023-5. View

2.
Hilsden R, Meddings J, Sutherland L . Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease. Gastroenterology. 1996; 110(5):1395-403. DOI: 10.1053/gast.1996.v110.pm8613043. View

3.
Brun P, Castagliuolo I, Di Leo V, Buda A, Pinzani M, Palu G . Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2006; 292(2):G518-25. DOI: 10.1152/ajpgi.00024.2006. View

4.
Yang S, Lin H, Lane M, Clemens M, Diehl A . Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A. 1997; 94(6):2557-62. PMC: 20127. DOI: 10.1073/pnas.94.6.2557. View

5.
Angulo P . Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346(16):1221-31. DOI: 10.1056/NEJMra011775. View